ArticleRenal failure2026
Proteinuria selectivity index as a predictor of remission and rituximab efficacy in primary membranous nephropathy: a single-center retrospective analysis.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe protein selectivity index (PSI) has been proposed as a prognostic marker in nephrotic syndrome, but its prognostic value in primary membranous nephropathy (PMN) has not been well established in the modern era of advanced diagnostics and therapeutics. This study assessed the predictive value of PSI for proteinuria remission and response to rituximab therapy.
methodsA total of 73 patients with PMN treated between September 2021 and September 2024 were included in this single-center retrospective study, all with at least six months of follow-up. PSI was calculated from serum and urinary immunoglobulin G and transferrin.
resultsThe optimal PSI cutoff for predicting complete remission was 0.303. Low-PSI (<0.303) patients had higher complete remission rates than high-PSI (≥0.303) patients (59.65% vs. 12.50%,
conclusionsIn conclusion, PSI predicts proteinuria remission and treatment response in PMN. Prospective multicenter studies are needed to validate its clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.